Patents Assigned to Nuray Chemicals Private Limited
-
Patent number: 11945788Abstract: The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.Type: GrantFiled: February 24, 2023Date of Patent: April 2, 2024Assignee: Nuray Chemicals Private LimitedInventors: Ramasamy Venkatragavan, Erugu Balaiah, Paramanandam Senthilkumaran, Guttha Jayaprasad, Manniyam Kailasam Selvam, Noti Krishnareddy, Sorakka Pichandi Parthipan, Murugan Arunkumar, Palaniswamy Premkumar, Salamuthu Kaliraj, Shanmugam Arumugam, Singavarapu Ajay Madhukar, Raman Silambarasan, Saminathan Karthick, Kudumudi Jayaraman Parthiban, Ravi Silambarasan
-
Patent number: 11760750Abstract: The present disclosure relates to a process for the preparing levoketoconazole, its salts, solvates, and solid-state forms thereof.Type: GrantFiled: March 9, 2023Date of Patent: September 19, 2023Assignee: Nuray Chemicals Private LimitedInventors: Ramasamy Venkatragavan, Senthilkumaran Paramanandam, Jayakumar Ayyamuthu, Andi Selvamani, Sengodan Manickam, Ravi Silambarasan, Murugan Arunkumar, Sorakka Pichandi Parthipan
-
Publication number: 20230149366Abstract: The disclosure relates to a dosage form comprising a hard gelatin or a HPMC capsule having a granule composition comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly a solid-state form comprising tafamidis and fumaric acid. The disclosure also relates to a tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly a solid-state form comprising tafamidis and fumaric acid. The solid dosage forms disclosed herein do not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and the compositions disclosed herein are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Type: ApplicationFiled: November 10, 2022Publication date: May 18, 2023Applicant: Nuray Chemicals Private LimitedInventors: Muthusamy SHANMUGAM, Singavarapu Ajay MADHUKAR, Palanisamy SIVAKUMAR, Thirunavukkarasu SAKTHIKUMAR
-
Publication number: 20230149365Abstract: The disclosure relates to a novel dosage form comprising hard gelatin or HPMC capsule having granule composition, spray dried or evaporated composition comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly tafamidis free acid fumaric acid cocrystal and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly tafamidis free acid fumaric acid cocrystal that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Type: ApplicationFiled: July 13, 2022Publication date: May 18, 2023Applicant: Nuray Chemicals Private LimitedInventors: Muthusamy SHANMUGAM, Ramasamy VENKATRAGAVAN, Singavarapu Ajay MADHUKAR, Erugu BALAIAH, Palanisamy SIVAKUMAR, Thirunavukkarasu SAKTHIKUMAR
-
Patent number: 11623920Abstract: The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.Type: GrantFiled: May 24, 2022Date of Patent: April 11, 2023Assignee: Nuray Chemicals Private LimitedInventors: Ramasamy Venkatragavan, Erugu Balaiah, Paramanandam Senthilkumaran, Guttha Jayaprasad, Manniyam Kailasam Selvam, Noti Krishnareddy, Sorakka Pichandi Parthipan, Murugan Arunkumar, Palaniswamy Premkumar, Salamuthu Kaliraj, Shanmugam Arumugam, Singavarapu Ajay Madhukar, Raman Silambarasan, Saminathan Karthick, Kudumudi Jayaraman Parthiban, Ravi Silambarasan
-
Patent number: 11523993Abstract: The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Type: GrantFiled: November 18, 2021Date of Patent: December 13, 2022Assignee: Nuray Chemicals Private LimitedInventors: Muthusamy Shanmugam, Ramasamy Venkatragavan, Singavarapu Ajay Madhukar, Erugu Balaiah, Palanisamy Sivakumar, Thirunavukkarasu Sakthikumar